Contraindicated (1)bortezomib will improve the amount or effect of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may well maximize mavacamten systemic publicity, causing coronary heart failure because of systolic dysfunction. This medication is used to treat specific different types of most cancers (including several https://andreslrvjm.smblogsites.com/26764576/detailed-notes-on-verteporfin